Researchers have discovered that a man with a gene mutation that causes early-onset Alzheimer's disease was protected from developing the disease until the age of 67 due to another mutation in a different gene that blocked the disease from affecting his entorhinal cortex, a brain region associated with memory and cognition. This finding could pave the way for new treatments that delay the onset of Alzheimer's and transform the approach to therapeutics for the disease. The New York Times reports: "This really holds the secret to the next generation of therapeutics," said Dr. Joseph F. Arboleda-Velasquez, a cell biologist at Massachusetts Eye and Ear in Boston and a member of the research team. Dr. Arboleda-Velasquez is a co-founder of a biotechnology company looking to produce drugs that could act on this research. A drug that delays the disease by two decades is not out of the question, said Dr. Diego Sepulveda-Falla, a neuropathologist at the University of Hamburg in Germany and a member of the research team. The mutation results in a potent version of a protein, Reelin, in the entorhinal cortex. That super-potent Reelin ultimately prevents tangled strands of tau proteins from sticking together and forming the structures that are a characteristic of Alzheimer's. The idea is to "go in with a syringe and treat only one area" of the brain, he said.

The man with what the researchers are calling "resilience" to Alzheimer's was part of a decades-long study of 6,000 people living in Colombia who have a gene mutation that causes Alzheimer's in middle age. Many have agreed to genetic testing, brain scans and, after they die, brain autopsies. A few years ago, the same research group in the current study identified a woman who also was protected from Alzheimer's. But in her case, resilience was caused by a mutation in a different gene, APOE. Instead of lacking clumps of tau in one small region of her brain, they were missing in her entire brain. But, the researchers say, they think the two patients are revealing a new pathway to treat Alzheimer's. The two genes that are mutated interrupt a molecular cascade of events needed for tau to aggregate in the brain. The findings were published in the journal Nature Medicine.

The World Health Organization (WHO) on Monday released guidance on non-sugar sweeteners (NSS), recommending against using them to control body weight. From the report: The recommendation is based on the findings of a systematic review of the available evidence which suggests that use of NSS does not confer any long-term benefit in reducing body fat in adults or children. Results of the review also suggest that there may be potential undesirable effects from long-term use of NSS, such as an increased risk of type 2 diabetes, cardiovascular diseases, and mortality in adults. The recommendation applies to all people except individuals with pre-existing diabetes and includes all synthetic and naturally occurring or modified non-nutritive sweeteners that are not classified as sugars found in manufactured foods and beverages, or sold on their own to be added to foods and beverages by consumers. Common NSS include acesulfame K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia and stevia derivatives.

The recommendation does not apply to personal care and hygiene products containing NSS, such as toothpaste, skin cream, and medications, or to low-calorie sugars and sugar alcohols (polyols), which are sugars or sugar derivatives containing calories and are therefore not considered NSS. "Replacing free sugars with NSS does not help with weight control in the long term. People need to consider other ways to reduce free sugars intake, such as consuming food with naturally occurring sugars, like fruit, or unsweetened food and beverages," says Francesco Branca, WHO Director for Nutrition and Food Safety. "NSS are not essential dietary factors and have no nutritional value. People should reduce the sweetness of the diet altogether, starting early in life, to improve their health."

"Astronomers have spotted the largest cosmic explosion ever witnessed, and it's 10 times brighter than any known exploding star, or supernova," reports CNN: The brightness of the explosion, called AT2021lwx, has lasted for three years, while most supernovas are only bright for a few months. The event, still being detected by telescopes, occurred nearly 8 billion light-years away from Earth when the universe was about 6 billion years old. The luminosity of the explosion is also three times brighter than tidal disruption events, when stars fall into supermassive black holes.

But what triggered such a long-lived, massive cosmic explosion? Astronomers said they think a supermassive black hole disrupted a vast gas or dust cloud, potentially thousands of times larger than our sun. It's possible that the cloud was drawn off the course of its orbit and went flying into the black hole, the researchers said. As the black hole swallowed pieces of the hydrogen cloud, shock waves likely reverberated through the cloud's remnants and into the swirling mass of material that orbits around the black hole...

The research team determined that the incredibly luminous event was nearly 100 times brighter than all the 100 billion stars in the Milky Way galaxy combined.
The New York Times calls its "one of the most violent and energetic acts of cosmic cannibalism ever witnessed, perhaps the biggest explosion seen yet in the history of the universe... [A] black hole perhaps a billion times as massive as the sun seems to be gorging on a humongous cloud of gas." "Most supernovae and tidal disruption events only last for a couple of months before fading away," said Philip Wiseman, an astrophysicist at the University of Southampton and the lead author of the new paper [published Thursday in the Monthly Notices of the Royal Astronomical Society]. "For something to be bright for two-plus years was immediately very unusual...."

He added that, with a total radiated energy equal to 100 supernovas, "it is one of the most luminous transients ever discovered." Jolt for jolt, that would put it in the company of colliding black holes. "Black holes colliding release energy in gravitational waves at an extreme luminosity — 10 billion times more 'powerful' than this explosion," Dr. Wiseman wrote. "But that power only lasts for 20 milliseconds," adding that this explosion has lasted years.

The Register reports: AI algorithms can screen for pancreatic cancer and predict whether patients will develop the disease up to three years before a human doctor can make the same diagnosis, according to research published in Nature on Monday.

Pancreatic cancer is deadly; the five-year survival rate averages 12 percent. Academics working in Denmark and the US believe AI could help clinicians by detecting pancreatic cancer at earlier stages, if the software can reliably predict which patients are at higher risk of developing the disease. The researchers trained AI algorithms on millions of medical records obtained in the Danish National Patient Registry and the US Veterans Affairs Corporate Data Warehouse... "Cancer gradually develops in the human body, often over many years and fairly slowly, until the disease takes hold," Chris Sander, the study's co-senior investigator and leader of a lab working at the Department of Systems Biology at Harvard Medical School, told The Register. "The AI system attempts to learn from signs in the human body that may relate to such gradual changes..."

"AI on real-world clinical records has the potential to produce a scalable workflow for early detection of cancer in the community, to shift focus from treatment of late-stage to early-stage cancer, to improve the quality of life of patients and to increase the benefit/cost ratio of cancer care," the paper reads... The study is still in its early stages, and the software cannot yet be used to run screening programs. Improvements are needed before even a trial can be conducted... Still, the team believes that as the technology improves and operating costs decrease, AI could become a valuable screening tool in the future. "Many types of cancer, especially those hard to identify and treat early, exert a disproportionate toll on patients, families and the healthcare system as a whole," said Søren Brunak, professor of disease systems biology and director of research at the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen, a co-senior investigator of the study, said in a statement.

"AI-based screening is an opportunity to alter the trajectory of pancreatic cancer, an aggressive disease that is notoriously hard to diagnose early and treat promptly when the chances for success are highest," he concluded.
Thanks to Slashdot reader Tony Hu for sharing the article.

"Astronomers have discovered 62 new moons orbiting the ringed planet Saturn," reports Space.com.

So while Jupiter remains the largest planet orbiting our sun — and shaped our solar system with its gravitational bulk — nonetheless the New York Times reports that "the fight over which planet has the most moons in its orbit has swung decisively in Saturn's favor." This month, the International Astronomical Union is set to recognize 62 additional moons of Saturn based on a batch of objects discovered by astronomers. The small objects will give Saturn 145 moons — eclipsing Jupiter's total of 95. "They both have many, many moons," said Scott Sheppard, an astronomer from the Carnegie Institution for Science in Washington, D.C. But Saturn "appears to have significantly more," he said, for reasons that are not entirely understood.

The newly discovered moons of Saturn are nothing like the bright object in Earth's night sky. They are irregularly shaped, like potatoes, and no more than one or two miles across. They orbit far from the planet too, between six million and 18 million miles, compared with larger moons, like Titan, that mostly orbit within a million miles of Saturn. Yet these small irregular moons are fascinating in their own right. They are mostly clumped together in groups, and they may be remnants of larger moons [150 miles across] that shattered while orbiting Saturn. [The article suggests later they may have been destroyed by collisions with other moons, or by impacts from asteroids or comets.]

"These moons are pretty key to understanding some of the big questions about the solar system," said Bonnie Buratti of NASA's Jet Propulsion Laboratory in California and the deputy project scientist on the upcoming Europa Clipper mission to Jupiter. "They have the fingerprints of events that took place in the early solar system."

The growing number of moons also highlights potential debates over what constitutes a moon. "The simple definition of a moon is that it's an object that orbits a planet," Dr. Sheppard said. An object's size, for the moment, doesn't matter.
The leader of one moon-discovering group told the Times there's "potentially thousands" of moons around Saturn and Jupiter.

And at least a few of the moons are circling Saturn in the opposite direction...

"A new experiment uses superconducting qubits to demonstrate that quantum mechanics violates what's called local realism," reports Ars Technica, "by allowing two objects to behave as a single quantum system no matter how large the separation between them." The experiment wasn't the first to show that local realism isn't how the Universe works — it's not even the first to do so with qubits. But it's the first to separate the qubits by enough distance to ensure that light isn't fast enough to travel between them while measurements are made. And it did so by cooling a 30-meter-long aluminum wire to just a few milliKelvin. Because the qubits are so easy to control, the experiment provides a new precision to these sorts of measurements.

And the hardware setup may be essential for future quantum computing efforts... Everyone working with superconducting qubits says that we will ultimately need to integrate thousands of them into a single quantum computer. Unfortunately, each of these qubits requires a considerable amount of space on a chip, meaning it gets difficult to make chips with more than a few hundred of them. So major players like Google and IBM ultimately plan to link multiple chips into a single computer (something the startup Rigetti is already doing).

For tens of thousands of qubits, however, we're almost certainly going to need so many chips that it gets difficult to keep them all in a single bit of cooling hardware. This means we're going to eventually want to link chips in different refrigeration systems — exactly what was demonstrated here. So this is an important demonstration that we can, in fact, link qubits across these sorts of systems.
Or, as long-time slashdot reader nounderscores puts it, "Imagine a beowulf cluster of these.

"The Qbits that Simon Storz et al at ETH Zurich entangled at the ends of 30m of cryogenically chilled wire not only put the last nail into the coffin of hidden variable theory by being so far apart, they also allow quantum computing to scale to multiple refrigeration systems."

From a Science magazine report, shared by schwit1: When neuropsychologist Bernhard Sabel put his new fake-paper detector to work, he was "shocked" by what it found. After screening some 5000 papers, he estimates up to 34% of neuroscience papers published in 2020 were likely made up or plagiarized; in medicine, the figure was 24%. Both numbers, which he and colleagues report in a medRxiv preprint posted on 8 May, are well above levels they calculated for 2010 -- and far larger than the 2% baseline estimated in a 2022 publishers' group report. "It is just too hard to believe" at first, says Sabel of Otto von Guericke University Magdeburg and editor-in-chief of Restorative Neurology and Neuroscience. It's as if "somebody tells you 30% of what you eat is toxic." His findings underscore what was widely suspected: Journals are awash in a rising tide of scientific manuscripts from paper mills -- secretive businesses that allow researchers to pad their publication records by paying for fake papers or undeserved authorship.

"Paper mills have made a fortune by basically attacking a system that has had no idea how to cope with this stuff," says Dorothy Bishop, a University of Oxford psychologist who studies fraudulent publishing practices. A 2 May announcement from the publisher Hindawi underlined the threat: It shut down four of its journals it found were "heavily compromised" by articles from paper mills. Sabel's tool relies on just two indicators -- authors who use private, noninstitutional email addresses, and those who list an affiliation with a hospital. It isn't a perfect solution, because of a high false-positive rate. Other developers of fake-paper detectors, who often reveal little about how their tools work, contend with similar issues. Still, the detectors raise hopes for gaining the advantage over paper mills, which churn out bogus manuscripts containing text, data, and images partly or wholly plagiarized or fabricated, often massaged by ghost writers.

Some papers are endorsed by unrigorous reviewers solicited by the authors. Such manuscripts threaten to corrupt the scientific literature, misleading readers and potentially distorting systematic reviews. The recent advent of artificial intelligence tools such as ChatGPT has amplified the concern. To fight back, the International Association of Scientific, Technical, and Medical Publishers (STM), representing 120 publishers, is leading an effort called the Integrity Hub to develop new tools. STM is not revealing much about the detection methods, to avoid tipping off paper mills. "There is a bit of an arms race," says Joris van Rossum, the Integrity Hub's product director. He did say one reliable sign of a fake is referencing many retracted papers; another involves manuscripts and reviews emailed from internet addresses crafted to look like those of legitimate institutions. Twenty publishers -- including the largest, such as Elsevier, Springer Nature, and Wiley -- are helping develop the Integrity Hub tools, and 10 of the publishers are expected to use a paper mill detector the group unveiled in April.

schwit1 shares a report from UPI: SpaceX confirmed Wednesday it signed a contract to launch the world's first commercial space station. The company also will perform manned space flights shortly after launching the station into orbit "no later than August 2025," SpaceX said in a statement. The Haven-1 space station is being built by Vast, a private aerospace company based in Long Beach, Calif. Its "mission is to contribute to a future where billions of people are living and thriving in space -- a future in which the human population and our resources expand far beyond our current imagination." Vast is solely funded by its billionaire founder and CEO Jed McCaleb.

SpaceX will use its Falcon 9 rocket to carry the Haven-1 station into orbit. Manned crews will then use the company's Dragon reusable spacecraft to get to the space station, docking for up to 30 days while in orbit. Vast plans for the initial module to become part of a larger 100-meter-long multi-module spinning space station with artificial gravity. SpaceX confirmed it also will provide crew training, as well as spacesuit and spacecraft ingress and egress exercises. SpaceX also will conduct mission simulations, as part of the agreement with Vast. Crew selection is underway, the company said Wednesday, and will be announced at a future date.

A personalized cancer vaccine made by BioNTech, the German company that produced the Pfizer-BioNTech COVID-19 vaccine, has shown promising results against pancreatic cancer. The vaccine, which teaches patients' immune systems to attack their tumors, provoked an immune response in half of the 16 patients treated, and those patients did not experience relapses of their cancer during the study. The New York Times reports: Researchers at Memorial Sloan Kettering Cancer Center in New York, led by Dr. Vinod Balachandran, extracted patients' tumors and shipped samples of them to Germany. There, scientists at BioNTech, the company that made a highly successful COVID vaccine with Pfizer, analyzed the genetic makeup of certain proteins on the surface of the cancer cells. Using that genetic data, BioNTech scientists then produced personalized vaccines designed to teach each patient's immune system to attack the tumors. Like BioNTech's COVID shots, the cancer vaccines relied on messenger RNA. In this case, the vaccines instructed patients' cells to make some of the same proteins found on their excised tumors, potentially provoking an immune response that would come in handy against actual cancer cells.

The study was small: Only 16 patients, all of them white, were given the vaccine, part of a treatment regimen that also included chemotherapy and a drug intended to keep tumors from evading people's immune responses. And the study could not entirely rule out factors other than the vaccine having contributed to better outcomes in some patients. [...] But the simple fact that scientists could create, quality-check and deliver personalized cancer vaccines so quickly -- patients began receiving the vaccines intravenously roughly nine weeks after having their tumors removed -- was a promising sign, experts said.

In patients who did not appear to respond to the vaccine, the cancer tended to return around 13 months after surgery. Patients who did respond, though, showed no signs of relapse during the roughly 18 months they were tracked. Intriguingly, one patient showed evidence of a vaccine-activated immune response in the liver after an unusual growth developed there. The growth later disappeared in imaging tests. "It's anecdotal, but it's nice confirmatory data that the vaccine can get into these other tumor regions," said Dr. Nina Bhardwaj, who studies cancer vaccines at the Icahn School of Medicine at Mount Sinai. "This is the first demonstrable success -- and I will call it a success, despite the preliminary nature of the study -- of an mRNA vaccine in pancreatic cancer," said Dr. Anirban Maitra, a specialist in the disease at the University of Texas MD Anderson Cancer Center, who was not involved in the study. "By that standard, it's a milestone."

The study has been published in the journal Nature.

An anonymous reader shares an excerpt from MIT Technology Review: Today, researchers announced yet another version of the human genome map, which they say combines the complete DNA of 47 diverse individuals -- Africans, Native Americans, and Asians, among other groups -- into one giant genetic atlas that they say better captures the surprising genetic diversity of our species. The new map, called a "pangenome," has been a decade in the making, and researchers say it will only get bigger, creating an expanding view of the genome as they add DNA from another 300 people from around the globe. It was published in the journal Nature today. People's genomes are largely alike, but it's the hundreds of thousands of differences, often just single DNA letters, that explain why each of us is unique. The new pangenome, researchers say, should make it possible to observe this diversity in more detail than ever before, highlighting so-called evolutionary hot spots as well as thousands of surprisingly large differences, like deleted, inverted, or duplicated genes, that aren't observable in conventional studies. The pangenome relies on a mathematical concept called a graph, which you can imagine as a massive version of connect-the-dots. Each dot is a segment of DNA. To draw a particular person's genome, you start connecting the numbered dots. Each person's DNA can take a slightly different path, skipping some numbers and adding others.

One payoff of the new pangenome could be better ways to diagnose rare diseases, although practical applications aren't easy to name. Instead, scientists say it's mainly giving them insight into some of the "dark matter" of the genome that's previously been hard to see, including strange regions of chromosomes that seem to share and exchange genes. For now, most biologists and doctors will stick to the existing "reference genome," the one first produced in draft form in 2001 and gradually improved. It answers most questions researchers are interested in, and all their computer tools work with it. The reason a reference genome is important is that when a new person's genome is sequenced, that sequence is projected onto the reference in order to organize and read the new data. Yet since the current reference is just one possible genome, missing bits that some people have, some information can't be analyzed and is usually ignored. Researchers call this effect "reference bias" or, more simply, the streetlamp problem. You don't see where you don't look.

Officials with NIH said they hoped the new update to the genome map would make gene research more "equitable." That's because the more different your genome is from the current reference, the more information about you could be missed. The existing reference is largely the DNA of one African-American man, although it includes segments from several other people as well. "If the genome you want to analyze has sequences that are not in that reference, they will be missed in the analysis," says Deanna Church, a consultant with the business incubator General Inception, who previously held a key role at NIH managing the reference genome. "In reality, the notion that there is a 'human genome' is really the problem," she says. "The current version is the simplest model you can make. It made sense when we started ... But now we need better models."

The first UK baby created with DNA from three people has been born after doctors performed a groundbreaking IVF procedure that aims to prevent children from inheriting incurable diseases. From a report: The technique, known as mitochondrial donation treatment (MDT), uses tissue from the eggs of healthy female donors to create IVF embryos that are free from harmful mutations their mothers carry and are likely to pass on to their children. Because the embryos combine sperm and egg from the biological parents with tiny battery-like structures called mitochondria from the donor's egg, the resulting baby has DNA from the mother and father as usual, plus a small amount of genetic material -- about 37 genes -- from the donor.

The process has led to the phrase "three-parent babies," though more than 99.8% of the DNA in the babies comes from the mother and father. Research on MDT, which is also known as mitochondrial replacement therapy (MRT), was pioneered in the UK by doctors at the Newcastle Fertility Centre. The work aimed to help women with mutated mitochondria to have babies without the risk of passing on genetic disorders. People inherit all their mitochondria from their mother, so harmful mutations in the "batteries" can affect all of the children a woman has.

Researchers have developed a "language" called Remmyo, which relies on specific facial muscle movements that can occur during rapid eye movement (REM) sleep. People who are capable of lucid dreaming can learn this language during their waking hours and potentially communicate while they are asleep. Ars Technica reports: "You can transfer all important information from lucid dreams using no more than three letters in a word," [sleep expert Michael Raduga], who founded Phase Research Center in 2007 to study sleep, told Ars. "This level of optimization took a lot of time and intellectual resources." Remmyo consists of six sets of facial movements that can be detected by electromyography (EMG) sensors on the face. Slight electrical impulses that reach facial muscles make them capable of movement during sleep paralysis, and these are picked up by sensors and transferred to software that can type, vocalize, and translate Remmyo. Translation depends on which Remmyo letters are used by the sleeper and picked up by the software, which already has information from multiple dictionaries stored in its virtual brain. It can translate Remmyo into another language as it is being "spoken" by the sleeper. "We can digitally vocalize Remmyo or its translation in real time, which helps us to hear speech from lucid dreams," Raduga said.

For his initial experiment, Raduga used the sleep laboratory of the Neurological Clinic of Frankfurt University in Germany. His subjects had already learned Remmyo and were also trained to enter a state of lucid dreaming and signal that they were in that lucid state during REM sleep. While they were immersed in lucid dreams, EMG sensors on their faces sent information from electrical impulses to the translation software. The results were uncertain. Based on attempts to translate planned phrases, Remmyo turned out to be anywhere from 13 to 81 percent effective, and in the interview, Raduga said he faced skepticism about the effectiveness of the translation software during the peer review process of his study, which is now published in the journal Psychology of Consciousness: Theory, Research and Practice. He still looks forward to making results more consistent by leveling up translation methods in the future. "The main problem is that it is hard to use only one muscle on your face to say something in Remmyo," said Raduga. "Unintentionally, people strain more than one muscle, and EMG sensors detect it all. Now we use only handwritten algorithms to overcome the problem, but we're going to use machine learning and AI to improve Remmyo decoding."

Louise Lerner writes via Phys.Org: Inside a lab, scientists marvel at a strange state that forms when they cool down atoms to nearly absolute zero. Outside their window, trees gather sunlight and turn them into new leaves. The two seem unrelated -- but a new study from the University of Chicago suggests that these processes aren't so different as they might appear on the surface. The study, published in PRX Energy on April 28, found links at the atomic level between photosynthesis and exciton condensates -- a strange state of physics that allows energy to flow frictionlessly through a material. The finding is scientifically intriguing and may suggest new ways to think about designing electronics, the authors said.

When a photon from the sun strikes a leaf, it sparks a change in a specially designed molecule. The energy knocks loose an electron. The electron, and the "hole" where it once was, can now travel around the leaf, carrying the energy of the sun to another area where it triggers a chemical reaction to make sugars for the plant. Together, that traveling electron-and-hole-pair is referred to as an "exciton." When the team took a birds-eye view and modeled how multiple excitons move around, they noticed something odd. They saw patterns in the paths of the excitons that looked remarkably familiar. In fact, it looked very much like the behavior in a material that is known as a Bose-Einstein condensate, sometimes known as "the fifth state of matter." In this material, excitons can link up into the same quantum state -- kind of like a set of bells all ringing perfectly in tune. This allows energy to move around the material with zero friction. (These sorts of strange behaviors intrigue scientists because they can be the seeds for remarkable technology -- for example, a similar state called superconductivity is the basis for MRI machines).

According to the models [...], the excitons in a leaf can sometimes link up in ways similar to exciton condensate behavior. This was a huge surprise. Exciton condensates have only been seen when the material is cooled down significantly below room temperature. It'd be kind of like seeing ice cubes forming in a cup of hot coffee. "Photosynthetic light harvesting is taking place in a system that is at room temperature and what's more, its structure is disordered -- very unlike the pristine crystallized materials and cold temperatures that you use to make exciton condensates," explained [study co-author Anna Schouten]. This effect isn't total -- it's more akin to "islands" of condensates forming, the scientists said. "But that's still enough to enhance energy transfer in the system," said Sager-Smith. In fact, their models suggest it can as much as double the efficiency. The findings open up some new possibilities for generating synthetic materials for future technology, said study co-author Prof. David Mazziotti. "A perfect ideal exciton condensate is sensitive and requires a lot of special conditions, but for realistic applications, it's exciting to see something that boosts efficiency but can happen in ambient conditions."

Arianespace CEO Stephane Israel says Europe will have to wait until the 2030s for a reusable rocket. Space.com reports: Arianespace is currently preparing its Ariane 6 rocket for a test flight following years of delays. Europe's workhorse Ariane 5, which has been operational for nearly 30 years, recently launched the JUICE Jupiter mission and now has only one flight remaining before retirement. Ariane 6 will be expendable, despite entering development nearly a decade ago, when reusability was being developed and tested in the United States, most famously by SpaceX.

"When the decisions were made on Ariane 6, we did so with the technologies that were available to quickly introduce a new rocket," said Israel, according to European Spaceflight. The delays to Ariane 6, however, mean that Europe lacks its own options for access to space. This issue was highlighted in a recent report from an independent advisory group to the European Space Agency. Israel stated that, in his opinion, Ariane 6 would fly for more than 10 years before Europe transitions to a reusable successor in the 2030s.

Aside from Arianespace, Europe is currently fostering a number of private rocket companies, including Rocket Factory Augsburg, Isar Aerospace, PLD Space and Skyrora, with some of these rockets to be reusable. However the rockets in development are light-lift, whereas Ariane 6 and its possible successor are much more capable, medium-heavy-lift rockets.

An anonymous reader shares a report: Broad-spectrum antibiotics are akin to nuclear bombs, obliterating every prokaryote they meet. They're effective at eliminating pathogens, sure, but they're not so great for maintaining a healthy microbiome. Ideally, we need precision antimicrobials that can target only the harmful bacteria while ignoring the other species we need in our bodies, leaving them to thrive. Enter SNIPR BIOME, a Danish company founded to do just that. Its first drug -- SNIPR001 -- is currently in clinical trials. The drug is designed for people with cancers involving blood cells. The chemotherapy these patients need can cause immunosuppression along with increased intestinal permeability, so they can't fight off any infections they may get from bacteria that escape from their guts into their bloodstream.

The mortality rate from such infections in these patients is around 15-20 percent. Many of the infections are caused by E. coli, and much of this E. coli is already resistant to fluoroquinolones, the antibiotics commonly used to treat these types of infections. The team at SNIPR BIOME engineers bacteriophages, viruses that target bacteria, to make them hyper-selective. They started by screening 162 phages to find those that would infect a broad range of E. coli strains taken from people with bloodstream or urinary tract infections, as well as from the guts of healthy people. They settled on a set of eight different phages. They then engineered these phages to carry the genes that encode the CRISPR DNA-editing system, along with the RNAs needed to target editing to a number of essential genes in the E. coli genome. This approach has been shown to prevent the evolution of resistance. After testing the ability of these eight engineered phages to kill the E. coli panel alone and in combination, they decided that a group of four of them was the most effective, naming the mixture SNIPR001. But four engineered phages do not make a drug; the team confirmed that SNIPR001 remains stable for five months in storage and that it does not affect any other gut bacteria.